The Phase II trial of arsenic trioxide combined with ascorbic acid for the treatment of non-APL AML presents a potential therapeutic option for patients with refractory or relapsed disease. Given the limited treatment options available for this patient population, the combination therapy could capture market interest, particularly if efficacy is demonstrated. However, the trial was terminated due to competing studies, which may limit its commercial viability. Stakeholders should assess the competitive landscape for AML therapies, particularly those targeting non-APL subtypes, and consider the implications of this termination on future research and development investments.